WO2011152662A3 - Ptd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물 - Google Patents
Ptd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물 Download PDFInfo
- Publication number
- WO2011152662A3 WO2011152662A3 PCT/KR2011/004015 KR2011004015W WO2011152662A3 WO 2011152662 A3 WO2011152662 A3 WO 2011152662A3 KR 2011004015 W KR2011004015 W KR 2011004015W WO 2011152662 A3 WO2011152662 A3 WO 2011152662A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ptd
- preventing
- fusion polypeptide
- ischemic diseases
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/02—Oxidoreductases acting on diphenols and related substances as donors (1.10) with a cytochrome as acceptor (1.10.2)
- C12Y110/02002—Ubiquinol-cytochrome-c reductase (1.10.2.2), i.e. electron-transport-complex-III
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 PTD-UQCRB 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물에 관한 것이다. 본 발명의 PTD-UQCRB 융합 폴리펩타이드는 매우 효과적으로 세포막을 통과하여 혈관신생을 유도할 뿐만 아니라 세포 독성을 일으키지도 아니하므로 허혈성 질환의 예방 및 치료를 위해 유용하게 사용될 수 있다.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/701,492 US8729021B2 (en) | 2010-06-01 | 2011-06-01 | PTD-UQCRB fusion polypeptide, and pharmaceutical composition for preventing and treating ischemic diseases, containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0051892 | 2010-06-01 | ||
KR1020100051892A KR101278221B1 (ko) | 2010-06-01 | 2010-06-01 | Ρtd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011152662A2 WO2011152662A2 (ko) | 2011-12-08 |
WO2011152662A9 WO2011152662A9 (ko) | 2012-04-19 |
WO2011152662A3 true WO2011152662A3 (ko) | 2012-06-07 |
Family
ID=45067192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/004015 WO2011152662A2 (ko) | 2010-06-01 | 2011-06-01 | Ptd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물 |
Country Status (3)
Country | Link |
---|---|
US (1) | US8729021B2 (ko) |
KR (1) | KR101278221B1 (ko) |
WO (1) | WO2011152662A2 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10287331B2 (en) | 2013-04-15 | 2019-05-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Mitochondrial proteins constructs and uses thereof |
KR101644599B1 (ko) * | 2014-10-14 | 2016-08-16 | 연세대학교 산학협력단 | 미토콘드리아 단백질 uqcrb 관련 질환 유전자발현 세포 구축 및 이를 활용한 uqcrb 기능조절 활성평가계 구축 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090033878A (ko) * | 2006-07-24 | 2009-04-06 | 포휴먼텍(주) | 허혈성 질환의 완화 및 치료를 위한 약학 조성물 및 그를 전달하기 위한 방법 |
KR20090121724A (ko) * | 2008-05-22 | 2009-11-26 | 한양대학교 산학협력단 | 아폽토시스 저해용 조성물 |
EP2184292A1 (en) * | 2008-11-10 | 2010-05-12 | Ulrich Kunzendorf | Anti-Apoptotic Fusion Proteins |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030062788A (ko) * | 2002-01-19 | 2003-07-28 | 포휴먼텍(주) | 생체분자 전달 펩타이드 mph1-btm 및 이것을포함하는 생명공학제품 |
KR100653726B1 (ko) * | 2004-11-01 | 2006-12-04 | 이미옥 | Nur77 유전자의 활성자를 포함하는 신규한 혈관신생제 |
-
2010
- 2010-06-01 KR KR1020100051892A patent/KR101278221B1/ko active IP Right Grant
-
2011
- 2011-06-01 WO PCT/KR2011/004015 patent/WO2011152662A2/ko active Application Filing
- 2011-06-01 US US13/701,492 patent/US8729021B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090033878A (ko) * | 2006-07-24 | 2009-04-06 | 포휴먼텍(주) | 허혈성 질환의 완화 및 치료를 위한 약학 조성물 및 그를 전달하기 위한 방법 |
KR20090121724A (ko) * | 2008-05-22 | 2009-11-26 | 한양대학교 산학협력단 | 아폽토시스 저해용 조성물 |
EP2184292A1 (en) * | 2008-11-10 | 2010-05-12 | Ulrich Kunzendorf | Anti-Apoptotic Fusion Proteins |
Non-Patent Citations (1)
Title |
---|
JUNG, H. ET AL., J BIOL CHEM., vol. 285, no. 15, 9 February 2010 (2010-02-09), pages 11584 - 11595 * |
Also Published As
Publication number | Publication date |
---|---|
KR20110132077A (ko) | 2011-12-07 |
US8729021B2 (en) | 2014-05-20 |
US20130072432A1 (en) | 2013-03-21 |
WO2011152662A2 (ko) | 2011-12-08 |
WO2011152662A9 (ko) | 2012-04-19 |
KR101278221B1 (ko) | 2013-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502223A1 (en) | A novel water dispersible granular composition | |
WO2013151668A3 (en) | Modified polynucleotides for the production of secreted proteins | |
WO2014093747A3 (en) | Antiperspirant and deodorant compositions | |
WO2011141685A3 (fr) | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants | |
WO2011060049A3 (en) | Spiro-oxindole mdm2 antagonists | |
WO2014014835A3 (en) | Criystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
EP4276180A3 (en) | Clostridium histolyticum enzyme | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
WO2012168430A3 (en) | Polypeptides | |
MX2011008262A (es) | Espiroamidas sustituidas como moduladores de b1r:. | |
WO2012156998A3 (en) | Amorphous mirabegron and processes for crystal forms of mirabegron | |
SG10201804817TA (en) | Delayed release compositions of linaclotide | |
WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
WO2014178078A3 (en) | Novel cloning, expression & purification method for the preparation of ranibizumab | |
EP2941263A4 (en) | PURIFIED EXTRACT ISOLATED FROM PSEUDOLYSIMACHION ROTUNDUM VAR SUBINTEGRUM CONTAINING A LARGE QUANTITY OF ACTIVE INGREDIENT, PREPARATION THEREOF AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT TO PREVENT INFLAMMATION, ALLERGY AND ASTHMA | |
WO2010102778A3 (de) | Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren | |
AP2012006230A0 (en) | A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition. | |
WO2011094430A3 (en) | Pro-angiogenic fragments of prominin-1 and uses thereof | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
WO2014203275A3 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
WO2012053009A3 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
WO2014121764A3 (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
MX2015015051A (es) | Formulaciones alternativas para polipeptidos de fusion tnfr:fc. | |
MX363699B (es) | Producto de comicronizacion que comprende acetato de ulipristal. | |
WO2010115125A3 (en) | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11790020 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13701492 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11790020 Country of ref document: EP Kind code of ref document: A2 |